These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 12471134)
1. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library. Beenhouwer DO; May RJ; Valadon P; Scharff MD J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134 [TBL] [Abstract][Full Text] [Related]
2. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development. May RJ; Beenhouwer DO; Scharff MD J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972 [TBL] [Abstract][Full Text] [Related]
3. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. Fleuridor R; Lees A; Pirofski L J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689 [TBL] [Abstract][Full Text] [Related]
4. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide. Valadon P; Nussbaum G; Oh J; Scharff MD J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050 [TBL] [Abstract][Full Text] [Related]
5. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Maitta RW; Datta K; Lees A; Belouski SS; Pirofski LA Infect Immun; 2004 Jan; 72(1):196-208. PubMed ID: 14688097 [TBL] [Abstract][Full Text] [Related]
7. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Zhang H; Zhong Z; Pirofski LA Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies. Mukherjee J; Kozel TR; Casadevall A J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877 [TBL] [Abstract][Full Text] [Related]
9. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans. McFadden DC; Casadevall A J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170 [TBL] [Abstract][Full Text] [Related]
10. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223 [TBL] [Abstract][Full Text] [Related]
11. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. Valadon P; Nussbaum G; Boyd LF; Margulies DH; Scharff MD J Mol Biol; 1996 Aug; 261(1):11-22. PubMed ID: 8760499 [TBL] [Abstract][Full Text] [Related]
12. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice. Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan. Maitta RW; Datta K; Pirofski LA Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457 [TBL] [Abstract][Full Text] [Related]
14. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943 [TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. Mukherjee J; Casadevall A; Scharff MD J Exp Med; 1993 Apr; 177(4):1105-16. PubMed ID: 8459205 [TBL] [Abstract][Full Text] [Related]
16. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens. Pirofski LA Trends Microbiol; 2001 Sep; 9(9):445-51. PubMed ID: 11553457 [TBL] [Abstract][Full Text] [Related]
17. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Devi SJ Vaccine; 1996 Jun; 14(9):841-4. PubMed ID: 8843625 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Datta K; Lees A; Pirofski LA Clin Vaccine Immunol; 2008 Aug; 15(8):1176-87. PubMed ID: 18524882 [TBL] [Abstract][Full Text] [Related]
19. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans]. Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans. Brandt S; Thorkildson P; Kozel TR Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]